Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE INTENSOL versus PARACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE INTENSOL versus PARACORT.
DEXAMETHASONE INTENSOL vs PARACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects via inhibition of phospholipase A2, reduction of prostaglandins and leukotrienes, and modulation of gene transcription.
Paracort is a corticosteroid that acts by binding to glucocorticoid receptors, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines and prostaglandins.
0.75-9 mg/day orally in divided doses every 6-12 hours; for anti-inflammatory/immunosuppressive effects, initial dose 0.75-9 mg/day; for cerebral edema, 10 mg IV then 4 mg IM/IV every 6 hours.
Prednisone 5-60 mg orally once daily; initial dose 5-15 mg daily; for acute conditions, up to 60 mg daily tapered over 2-3 weeks.
None Documented
None Documented
Terminal elimination half-life: 36-54 hours (adults); clinically, biological half-life (duration of HPA axis suppression) is longer (24-72 hours).
Terminal elimination half-life is 3.5 hours (range 2.5–4.5 hours) in adults with normal renal function; prolonged to up to 10–15 hours in severe renal impairment (CrCl <30 mL/min).
Renal (approximately 65-80% as metabolites, <10% as unchanged drug); biliary/fecal (minor).
Renal elimination of unchanged drug accounts for approximately 70% of the dose; biliary/fecal excretion accounts for 20%; the remainder is metabolized and excreted as inactive metabolites.
Category D/X
Category C
Corticosteroid
Corticosteroid